Spero Therapeutics, Inc. Share Price & Technical Analysis
SPRO · $2.57 (-6.20%)
Healthcare / Biotechnology
$2.57
-6.20%
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including p…
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-7% return in Jun, -1% avg return in past 3 year Jun month.
19% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 0% | 10% | 9% | 12% | -7% | – | – | – | – | – | – | 19% |
| 25 | -10% | 0% | -12% | 0% | 257% | 16% | -21% | -9% | -5% | 26% | 0% | 0% | 243% |
| 24 | 0% | 7% | 6% | -18% | 0% | -7% | 8% | 0% | -7% | -8% | -8% | -9% | -36% |
| 23 | 6% | -21% | 0% | 29% | -6% | -12% | 7% | -6% | -20% | -8% | 0% | 36% | 4% |
| 22 | -27% | -20% | -9% | -30% | -75% | -42% | -12% | 14% | 150% | 0% | -5% | -11% | -67% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$164.15M
P/E ratio
10.5
52W high
$3.22
52W low
$1.80
Volume
11,25,201
Beta
1.46
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Spero Therapeutics, Inc. share price today?
- Spero Therapeutics, Inc. (SPRO) last traded around $2.57 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SPRO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SPRO. Download the app for real-time alerts.
- How can I analyze Spero Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.